June 06, 2015 –  On May 22, 2015, the European Medicines Agency (EMA) has recommended granting a marketing authorisation for Unituxin (Dinutuximab) for the treatment of high-risk neuroblastoma, a type of cancer that most often occurs in young children. Unituxin (Dinutuximab) is to be used in children …

Treatment with Unituxin (Dinutuximab) for high-risk neuroblastoma in children recommended by EMA Read more »